sk&f 82958 has been researched along with Parkinson Disease, Secondary in 16 studies
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Talipexole was more potent than pramipexole (10 vs." | 1.30 | Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys. ( Domino, EF; Kohno, Y; Ni, L; Sasa, M; Zhang, H, 1997) |
| "Trihexyphenidyl was then studied in combination with the selective dopamine receptor D1 agonist SKF-82958 [(+/-)-6-chloro-7-8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro- 1H-benzazepine hydrobromide] and the selective D2 agonist N-0923 [(-)2-(N-propyl-N-2-thienylethyl)amino-5-hydroxytetralin HCl] on rotational behavior in five 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned hemiparkinsonian monkeys." | 1.30 | Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys. ( Domino, EF; Ni, L, 1998) |
| " In contrast, chronic administration of the D1-like receptor agonist CY 208243 to 6-OHDA-lesioned rats dramatically enhanced deltaFosB-like immunoreactivity in striatal neurons projecting to the substantia nigra." | 1.29 | Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. ( Bedard, PJ; Blanchet, P; Chen, JS; Doucet, JP; Grondin, R; Hope, BT; Iadarola, MJ; Jasmin, BJ; Nakabeppu, Y; Nestler, EJ; Robertson, GS; St-Jean, M; Wigle, N, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (75.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Samadi, P | 1 |
| Grégoire, L | 1 |
| Bédard, PJ | 5 |
| Bibbiani, F | 1 |
| Oh, JD | 1 |
| Kielaite, A | 1 |
| Collins, MA | 1 |
| Smith, C | 1 |
| Chase, TN | 1 |
| Nomoto, M | 1 |
| Fukuda, T | 1 |
| Doucet, JP | 1 |
| Nakabeppu, Y | 1 |
| Hope, BT | 1 |
| Nestler, EJ | 1 |
| Jasmin, BJ | 1 |
| Chen, JS | 1 |
| Iadarola, MJ | 1 |
| St-Jean, M | 1 |
| Wigle, N | 1 |
| Blanchet, P | 1 |
| Grondin, R | 4 |
| Robertson, GS | 1 |
| Blanchet, PJ | 3 |
| Goulet, M | 2 |
| Di Paolo, T | 2 |
| Domino, EF | 3 |
| Ni, L | 2 |
| Zhang, H | 1 |
| Kohno, Y | 1 |
| Sasa, M | 1 |
| Kuno, S | 1 |
| Maneuf, YP | 1 |
| Crossman, AR | 1 |
| Brotchie, JM | 2 |
| Andringa, G | 1 |
| Lubbers, L | 1 |
| Drukarch, B | 1 |
| Stoof, JC | 1 |
| Cools, AR | 1 |
| Calon, F | 1 |
| Morissette, M | 1 |
| Fox, SH | 1 |
| Rupniak, NM | 1 |
| Boyce, S | 1 |
| Steventon, M | 1 |
| Iversen, SD | 1 |
| Silverman, PB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Long-term Effects of Amantadine in Parkinsonian's Suffering From Dyskinesia Induced by Levodopa: Study Randomised Double-blind, Placebo - Cessation of a Chronic Prescription. STUDY AMANDYSK.[NCT00632762] | Phase 4 | 80 participants (Anticipated) | Interventional | 2007-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 other studies available for sk&f 82958 and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine; Dopamine Agents; Dopa | 2003 |
Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Benzodiazepines; Disease | 2005 |
The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzazepines; Callithri | 1993 |
Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.
Topics: Animals; Bacterial Proteins; Base Sequence; Benzazepines; Blotting, Western; Cabergoline; Corpus Str | 1996 |
Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Brain; Dopamine Agents; Dopamin | 1996 |
Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Catecholamines; Dopamine Agonis | 1996 |
Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Azepines; Basal Ganglia Diseases; Behavior, Animal; Benzazepines; Ben | 1997 |
Selective full dopamine D1-like (SKF-82958) and D2-like (N-0923) agonist combination in the MPTP monkey model of hemiparkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Disease Models, Animal; Dopamin | 1997 |
Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Benzazepin | 1997 |
The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Benzazepines; Benzoxazines; Dopamine Agonists; gamma-Aminobutyric Acid; Loco | 1997 |
Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Benzazepines; Dopamine Agonists; Dose-Response Relationship, Drug; Dr | 1998 |
The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF 82958.
Topics: Animals; Antiparkinson Agents; Arm; Behavior, Animal; Benzazepines; Dopamine Agents; Dopamine Agonis | 1999 |
125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Basal | 2000 |
5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Disease Models, Animal; Dopamine Agon | 2000 |
Weak antiparkinsonian activity of the D1 agonist C-APB (SKF 82958) and lack of synergism with a D2 agonist in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzazepines; Dopamine | 1992 |
Sensitization, response fluctuation and long-term effect of SKF-82958 and bromocriptine in the hemi-parkinsonian rat.
Topics: Animals; Benzazepines; Bromocriptine; Dopamine Agents; Dose-Response Relationship, Drug; Female; Mot | 1992 |